Challenging the U.S. Food and Drug Administration’s current approach to evaluating and approving adipose-based cell therapies used in reparative medicine, a group of researchers proposes a new path forward that focuses on patient safety and includes evidence-based medical practice. Details of this new path forward and a response from the FDA are both published in Stem Cells and Development.
Read More
Health Rss 